Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer
Twelve patients with hormone-refractory prostate cancer were treated with combination chemotherapy of etoposide, epirubicin and carboplatin (EEC). At relapse, all patients had metastases to the bone and/or soft tissues. The median number of courses was 3 (range 1-10). Epirubicin was not administered in 6 patients because of heart disease. Three patients (25%) had a partial response and 8 (67%) showed no change. The overall response rate was 92%. Pain relief was observed in 4 patients (44%). Four patients were still alive after a mean observation period of 18 months (range 4-36 months), while 8 died with a mean survival period of 11 months (range 7-15 months). Nausea, appetite loss, and alopecia were observed in some patients. All except one patient experienced bone marrow suppression, 5 of whom were treated with granulocyte-colony stimulating factor. EEC chemotherapy in hormone-refractory prostate cancer is considered to be more effective than other kinds of chemotherapy, whereas it frequently induces bone marrow suppression.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1996 |
|---|---|
| Erschienen: |
1996 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
International urology and nephrology - 28(1996), 1 vom: 10., Seite 79-85 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fuse, H [VerfasserIn] |
|---|
| Themen: |
3Z8479ZZ5X |
|---|
| Anmerkungen: |
Date Completed 16.10.1996 Date Revised 05.09.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM087105365 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM087105365 | ||
| 003 | DE-627 | ||
| 005 | 20231222071020.0 | ||
| 007 | tu | ||
| 008 | 231222s1996 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0291.xml |
| 035 | |a (DE-627)NLM087105365 | ||
| 035 | |a (NLM)8738624 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fuse, H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer |
| 264 | 1 | |c 1996 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 16.10.1996 | ||
| 500 | |a Date Revised 05.09.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Twelve patients with hormone-refractory prostate cancer were treated with combination chemotherapy of etoposide, epirubicin and carboplatin (EEC). At relapse, all patients had metastases to the bone and/or soft tissues. The median number of courses was 3 (range 1-10). Epirubicin was not administered in 6 patients because of heart disease. Three patients (25%) had a partial response and 8 (67%) showed no change. The overall response rate was 92%. Pain relief was observed in 4 patients (44%). Four patients were still alive after a mean observation period of 18 months (range 4-36 months), while 8 died with a mean survival period of 11 months (range 7-15 months). Nausea, appetite loss, and alopecia were observed in some patients. All except one patient experienced bone marrow suppression, 5 of whom were treated with granulocyte-colony stimulating factor. EEC chemotherapy in hormone-refractory prostate cancer is considered to be more effective than other kinds of chemotherapy, whereas it frequently induces bone marrow suppression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antineoplastic Agents, Hormonal |2 NLM | |
| 650 | 7 | |a Epirubicin |2 NLM | |
| 650 | 7 | |a 3Z8479ZZ5X |2 NLM | |
| 650 | 7 | |a Etoposide |2 NLM | |
| 650 | 7 | |a 6PLQ3CP4P3 |2 NLM | |
| 650 | 7 | |a Carboplatin |2 NLM | |
| 650 | 7 | |a BG3F62OND5 |2 NLM | |
| 700 | 1 | |a Muraishi, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Fujishiro, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Katayama, T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International urology and nephrology |d 1971 |g 28(1996), 1 vom: 10., Seite 79-85 |w (DE-627)NLM000017531 |x 1573-2584 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:1996 |g number:1 |g day:10 |g pages:79-85 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 1996 |e 1 |b 10 |h 79-85 | ||